Anon. FDA warns against consuming dietary supplements containing tiratricol. FDA. 2000. Available at: www.fda.gov/bbs/topics/ANSWERS/ANS01057.html
Asteria C, Rajanayagam O, Collingwood TN, et al. Prenatal diagnosis of thyroid hormone resistance. J Clin Endocrinol Metab 1999;84:405-10. View abstract.
Bauer BA, Elkin PL, Erickson D, Klee GG, Brennan MD. Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol. Mayo Clin Proc 2002;77(6):587-90. View abstract.
Beck-Peccoz P, Sartorio A, De Medici C, et al. Dissociated thyromimetic effects of 3, 5, 3'-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels. J Endocrinol Invest 1988;11:113-8. View abstract.
Bentin J, Desir D, Mockel J. Triac (3,5,3'-triiodo-thyroacetic acid) induced "pseudohypothyroidism". Acta Clin Belg 1984;39:285-9.
Bracco D, Morin O, Schutz Y, et al. Comparison of the metabolic and endocrine effects of 3,5,3'-triiodothyroacetic acid and thyroxine. J Clin Endocrinol Metab 1993;77:221-8. View abstract.
Chow WS, Lam KS. An overweight woman with galactorrhoea. Postgrad Med J 1998;74:121-2.
Cohen-Lehman J, Charitou MM, Klein I. Tiratricol-induced periodic paralysis: a review of nutraceuticals affecting thyroid function. Endocr Pract 2011;17(4):610-5. View abstract.
Dulgeroff AJ, Geffner ME, Koyal SN, et al. Bromocriptine and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 1992;75:1071-5. View abstract.
FDA. FDA warns against consuming triax metabolic accelerator. Available at: www.fda.gov/bbs/topics/ANSWERS/ANS00984.html
FDA. List of orphan designations and approvals. Office of Orphan Products Development. Available at: www.fda.gov/orphan/designat/list.htm.
Ferner RE, Burnett A, Rawlins MD. Triiodothyroacetic acid abuse in a female body builder. Lancet 1986;1:383.
Hawkey CM, Olsen EG, Symons C. Production of cardiac muscle abnormalities in offspring of rats receiving triiodothyroacetic acid (triac) and the effect of beta adrenergic blockade. Cardiovasc Res 1981;15:196-205. View abstract.
Heim J. [Hypothyroidism of central origin corrected by the cessation of Triac therapy]. Ann Med Interne (Paris) 1982;133:588-9. View abstract.
Jaffiol C, Daures JP, Nsakala N, et al. [Long term follow up of medical treatment of differentiated thyroid cancer]. Ann Endocrinol (Paris) 1995;56:119-26. View abstract.
Jean-Pastor MJ, Jean P, Biour M, et al. [Hepatopathies from treatment with a specialty drug combination of tiratricol-cyclovalone-retinol]. J Toxicol Clin Exp 1986;6:115-21.
Kunitake JM, Hartman N, Henson LC, et al. 3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance. J Clin Endocrinol Metab 1989;69:461-6. View abstract.
Lerman JL, Pitt-rivers R. Physiological activity of triiodo and tetraiodothyroacetic acid on blood-cholesterol levels. Lancet 1956;1:885-9.
Lind P, Langsteger W, Koltringer P, et al. 3,5,3'-Triiodothyroacetic acid (TRIAC) effects on pituitary thyroid regulation and on peripheral tissue parameters. Nuklearmedizin 1989;28:217-20. View abstract.
Lledo Carreres M, Lajo Garrido JL, Gonzalez Rico M, et al. Toxic internuclear ophthalmoplegia related to antiobesity treatment. Ann Pharmacother 1992;26:1457-8.
McDermott MT, Ridgway EC. Central hyperthyroidism. Endocrinol Metab Clin North Am 1998;27:187-203. View abstract.
Mechelany C, Schlumberger M, Challeton C, et al. TRIAC (3,5,3'-triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with L-thyroxine. Clin Endocrinol (Oxf) 1991;35:123-8. View abstract.
Menegay C, Juge C, Burger AG. Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. Acta Endocrinol (Copenh) 1989;121:651-8. View abstract.
Mueller-Gaertner HW, Schneider C. 3,5,3'-Triiodothyroacetic acid minimizes the pituitary thyrotrophin secretion in patients on levo-thyroxine therapy after ablative therapy for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1988;28:345-51. View abstract.
Nicolini U, Venegoni E, Acaia B, et al. Prenatal treatment of fetal hypothyroidism: is there more than one option? Prenat Diagn 1996;16:443-8. View abstract.
Olsen EG, Symons C, Hawkey C. Effect of triac on the developing heart. Lancet 1977;2:221-3. View abstract.
Pitt-Rivers R. Physiological activity of the acetic acid analogues of some iodinated thyronines. Lancet 1953;2:234.
Radetti G, Persani L, Molinaro G, et al. Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid 1997;7:775-8. View abstract.
Scally MC, Hodge A. A report of hypothyroidism induced by an over-the-counter fat loss supplement (Tiratricol). Int J Sport Nutr Exerc Metab 2003;13(1):112-6. View abstract.
Sherman SI, Ladenson PW. Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab 1992;75:901-5. View abstract.
Sherman SI, Ringel MD, Smith MJ, et al. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 1997;82:2153-8. View abstract.
Takeda T, Suzuki S, Liu RT, et al. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab 1995;80:2033-40. View abstract.